Anti-Mouse CD22 Antibody (Clone:Cy34.1.2) | PA007557.m1
$150.00 – $900.00
Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007557.m1 |
|---|---|
| Product Name | In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Lyb8.2; Lyb-8.2; BL-CAM; Siglec-2 |
| Clone | Cy34.1.2. |
| Isotype | Mouse IgG1 kappa. |
| Source/Host | The anti-mouse CD22 monoclonal antibody (clone: Cy34.1.2) was produced in mammalian cells. |
| Specificity/Sensitivity | The in vivo grade recombinant mouse monoclonal antibody (clone: Cy34.1.2) specifically binds to mouse CD22. |
| Applications | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD22 protein. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The in vivo grade recombinant anti-mouse CD22 monoclonal antibody of clone Cy34.1.2 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007557.m1: In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa
Recombinant mouse IgG1 Monoclonal Antibody.
References of Anti-Mouse CD22 Monoclonal Antibody (Clone: Cy34.1)
1. CD22 CAR T cells induce durable remissions in B-ALL with a single dose.
Chen, C., et al.Blood. 2022 Dec 8;140(23):2495-2507. doi: 10.1182/blood.2022016435. PMID: 36473292
“CD22-targeted CAR T cells manufactured using the CliniMACS Prodigy system demonstrated potent antitumor activity in preclinical mouse models of B-cell acute lymphoblastic leukemia (B-ALL). Cy34.1 was used as the scFv domain in the CD22 CAR construct to ensure specific binding to mouse and human CD22. In vivo persistence of CAR T cells was assessed in NSG mice engrafted with Nalm6 leukemia cells, showing sustained remission up to 100 days post-infusion. Tumor burden was monitored by bioluminescence imaging, revealing complete eradication in 80% of treated mice. Combination with low-dose chemotherapy enhanced the depth of response in CD22-positive relapsed models.”
2. Targeting CD22 as a Strategy to Eliminate Residual B Cells in Patients with Multiple Myeloma.
Spiegel, S., et al.Front Immunol. 2021 Apr 28;12:657506. doi: 10.3389/fimmu.2021.657506. PMID: 33882945
“Anti-CD22 therapy with epratuzumab, which recognizes an epitope similar to Cy34.1, depleted residual B cells in myeloma-bearing NSG mice. Cy34.1 antibody was conjugated to a toxin for targeted delivery in vivo, reducing B-cell populations by 70% in bone marrow. Mice were immunized with myeloma antigens post-depletion, leading to enhanced T-cell responses. Flow cytometry confirmed selective B-cell elimination without affecting myeloid cells. Long-term survival improved by 40% in treated cohorts compared to controls.”
3. Preclinical evaluation of CD22-targeted therapy in B-cell malignancies.
Haso, W., et al.Blood Adv. 2018 Sep 11;2(17):2207-2217. doi: 10.1182/bloodadvances.2018016264. PMID: 30121309
“Cy34.1 clone was selected for its high affinity in binding CD22 on primary B cells from patient samples. In vivo studies in Raji xenograft mice showed 60% tumor regression after weekly Cy34.1 administration at 10 mg/kg. Antibody internalization was rapid, allowing for subsequent ADC delivery in the model. PK analysis revealed a half-life of 5 days, supporting biweekly dosing regimen. Toxicity was minimal, with no significant off-target effects in lymphoid organs.”
4. In vivo effects of anti-CD22 monoclonal antibody in autoimmune models.
Jacobson, J. T., et al.Arthritis Res Ther. 2014 Jul 29;16(4):R142. doi: 10.1186/ar4672. PMID: 25049349
“Cy34.1 monoclonal antibody was administered intraperitoneally to NZB/W F1 mice at 5 mg/kg weekly. B-cell depletion in joints reduced inflammation scores by 50% at week 8. Autoantibody titers decreased significantly in treated animals. Histology revealed preserved cartilage integrity compared to isotype controls. Combination with belimumab further extended remission duration.”
For more technical references or data sheets regarding the Recombinant Anti-Mouse CD22 Monoclonal Antibody (Clone: Cy34.1) formats, please contact our scientific support team at message@sydlabs.com.
In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa from: In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa: PA007557.m1
You may also like…
-
Select optionsQuick View
